A study to investigate the safety, tolerability, and pharmacokinetics of AZD7503 in Japanese healthy participants.

Study identifier:D9230C00005

ClinicalTrials.gov identifier:NCT06093542

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Randomised, Single-blind, Single center, Placebo-controlled, Phase I study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participants.

Medical condition

Heathy participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7053, Placebo

Sex

All

Actual Enrollment

12

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 25 Oct 2023
Estimated Primary Completion Date: 20 Mar 2024
Estimated Study Completion Date: 20 Mar 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria